OPERATING SEGMENT AND GEOGRAPHIC INFORMATION

12 Months Ended

Dec. 31, 2012

Segment Reporting [Abstract]

Operating Segment And Geographic Information

OPERATING SEGMENT AND GEOGRAPHIC INFORMATION

Our company’s chief operating decision-maker is the Chief Executive Officer, who regularly evaluates our performance based on net sales and gross profit. The preparation of this segment analysis requires management to make estimates and assumptions around expenses below the gross profit level. While we believe the segment information to be directionally correct, actual results could differ from the estimates and assumptions used in preparing this information.

We have three reportable operating segments, Clinical Laboratories, Pharmacogenomic Services and Diagnostic Tools. These lines of business are complementary with the Pharmacogenomics Services driving innovation and leading to kit production in our Diagnostic Tools segment and new tests in our Clinical Laboratories.

The accounting policies of the segments are the same as the policies discussed in Footnote 2 – Summary of Significant Accounting Policies.

Segment information for the years ended December 31, 2012, 2011 and 2010 is as follows:

	Dollars in Thousands
	2012
	Clinical Laboratories			Pharmacogenomic Services			Diagnostic Tools			Total
Net Sales	$	17,453		$	1,876		$	12,151		$	31,480
Gross Profit	8,487			829			5,694			15,010
Net Loss before Taxes	(6,564		)	(310		)	(1,307		)	(8,181		)
Income Tax Expense	—			—			146			146
Net Loss	$	(6,564	)	$	(310	)	$	(1,453	)	$	(8,327	)
Depreciation/Amortization	$	1,727		$	233		$	318		$	2,278
Interest Expense	(840		)	(11		)	(37		)	(888		)
	December 31, 2012
Total Assets	$	26,902		$	2,294		$	9,595		$	38,791
Goodwill	6,918			$	—		$	—		6,918

	Dollars in Thousands
	2011
	Clinical Laboratories			Pharmacogenomic Services			Diagnostic Tools		Total
Net Sales	$	16,038		$	2,280		$	13,653	$	31,971
Gross Profit	9,478			1,050			7,909		18,437
Net Income (Loss) before Taxes	(11,016		)	(354		)	1,633		(9,737		)
Income Tax Expense	—			—			45		45
Net Income (Loss)	$	(11,016	)	$	(354	)	$	1,588	$	(9,782	)
Depreciation/Amortization	$	1,568		$	242		$	291	$	2,101
Restructure	29			—			12		41
Interest Expense	(958		)	—			—		(958		)
	December 31, 2011
Total Assets	$	22,032		$	1,636		$	9,894	$	33,562
Goodwill	6,440			—			—		6,440

	Dollars in Thousands
	2010
	Clinical Laboratories			Pharmacogenomic Services			Diagnostic Tools			Total
Net Sales	$	3,606		$	1,373		$	15,069		$	20,048
Gross Profit	1,481			(43		)	8,326			9,764
Net Loss before Taxes	(1,829		)	(696		)	(459		)	(2,984		)
Income Tax Expense	—			—			150			150
Net Loss	$	(1,829	)	$	(696	)	$	(609	)	$	(3,134	)
Depreciation/Amortization	$	119		$	186		$	403		$	708
Restructure	65			—			73			138
Interest Expense	(1		)	—			(3		)	(4		)
	December 31, 2010
Total Assets	$	22,945		$	1,686		$	7,396		$	32,027
Goodwill	6,275			—			—			6,275

Net sales for the year ended December 31, 2012, 2011 and 2010 by country were as follows:

	Dollars in Thousands
	Years Ended December 31,
	2012		2011		2010
United States	$	22,727	$	22,626	$	8,729
Italy	2,524		3,152		3,294
United Kingdom	1,703		778		1,412
Germany	907		750		1,366
France	679		758		1,160
All Other Countries	2,940		3,907		4,087
Total	$	31,480	$	31,971	$	20,048

No other country accounted for more than 5% of total net sales.

More than 95% of our long-lived assets are located within the United States. Substantially all of the remaining long-lived assets are located within Europe.